Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers
(MedPage Today) -- An investigational PET imaging agent -- zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab -- identified clear cell renal cell carcinoma (ccRCC) with high sensitivity and specificity, according to results from the phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 13, 2023 Category: Hematology Source Type: news
Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer
MONDAY, March 13, 2023 -- For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2023 Category: Pharmaceuticals Source Type: news
Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023 Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023
Key data in renal cell carcinoma from ASCO GU 2023 include phase 3 results on girentuximab and updates of CheckMate 9ER and COSMIC-313, which examined combination therapies in the frontline setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
New BAP1 Finding Could Be Key to Regulating Mesothelioma
Mesothelioma is a rare cancer most often caused by exposure to asbestos fibers. Our researchers at the University of Hawaii Cancer Center have discovered how asbestos causes mesothelioma, which we linked mainly to the protein HMGB1.
After several years of studying a unique mesothelioma epidemic in Cappadocia, Turkey, we noted that in certain families, up to 50% of family members developed mesothelioma. We demonstrated that susceptibility to mesothelioma was transmitted genetically from one generation to the next.
Following this discovery, several U.S. families with multiple mesothelioma cases contacted us...
Source: Asbestos and Mesothelioma News - March 9, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Taking a Break From TKIs Unlikely to Shorten Survival Taking a Break From TKIs Unlikely to Shorten Survival
A unique study in patients with renal cell carcinoma on tyrosine kinase inhibitors (TKIs) shows that taking a break from the drugs is feasible and cost-effective.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Genomic Sequencing Predicts Risk of Kidney Cancer Relapse Genomic Sequencing Predicts Risk of Kidney Cancer Relapse
Twelve genetic mutations in clear-cell renal cell carcinoma may predict which patients will experience recurrence; they could also help personalize adjuvant treatment, researchers say.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC
First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mutational Signature Indicates Risk of Kidney Cancer Recurrence
DNA sequencing can identify mutations that predict recurrence of renal cell carcinoma and may help low-risk patients avoid unnecessary treatment, a study finds. (Source: The Scientist)
Source: The Scientist - March 1, 2023 Category: Science Tags: News & Opinion Source Type: news
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
(MedPage Today) -- SAN FRANCISCO -- First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC).
An update of the CheckMate 9ER trial, which... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 20, 2023 Category: Hematology Source Type: news
Certain pesticides linked to kidney cancer in agricultural workers
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2020/7/papers/kidney-cancer/thumb894915.jpg?itok=fVpzjugS" /><br /><p>New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Episode 6: Second-Line Treatment of Renal Cell Carcinoma Episode 6: Second-Line Treatment of Renal Cell Carcinoma
Drs Sumanta Pal and Martin Voss discuss second-line treatment of renal cell carcinoma, including current studies and agents used in the refractory setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Cryoablation More Effective for Some Early-Stage Renal Cell Carcinomas
MONDAY, Dec. 5, 2022 -- For patients with early-stage renal cell carcinoma, heat-based thermal ablation is associated with increased cancer-specific mortality with tumor size 3.1 to 4 cm, while cancer-specific mortality is similar for heat-based... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2022 Category: Pharmaceuticals Source Type: news
Hope for thousands battling kidney cancer: Study reveals existing lung drug might help fight disease
Renal cell carcinoma is one of the most common cancers in the UK and US and has a 50 per cent mortality rate - partially because most patients show no symptoms until it's at a late stage. (Source: the Mail online | Health)
Source: the Mail online | Health - November 23, 2022 Category: Consumer Health News Source Type: news
Atezolizumab Fails to Improve Outcomes in Postsurgery Kidney Cancer Atezolizumab Fails to Improve Outcomes in Postsurgery Kidney Cancer
"Our results add to an emerging body of literature around the role of adjuvant immunotherapy for renal cell carcinoma. With the longest duration of follow-up to date to our knowledge."MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Allogeneic CAR T-Cell Therapy Shows Early Promise in Kidney Cancer
(MedPage Today) -- A novel chimeric antigen receptor (CAR) T-cell therapy targeting CD70 showed encouraging activity in a small group of patients with advanced clear cell renal cell carcinoma (ccRCC), with one patient achieving a complete response... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 15, 2022 Category: Hematology Source Type: news
